FINWIRES · TerminalLIVE
FINWIRES

Moody's Upgrades Ratings of Four Major Indian Companies After Change in Rating Methodology

By

Moody's has upgraded the ratings of four major corporates in India as part of the revision of its sovereign-linked ratings methodology, which replaces its earlier framework, according to a Friday statement issued by the ratings agency.

In this process, Tata Consultancy Services' (NSE:TCS, BOM:532540) long-term local currency issuer rating was upgraded to A2 from Baa1. The long-term local currency issuer rating of another technology giant, Infosys (NSE:INFY, BOM:500209), was upgraded to A2 from Baa1.

Both companies are the only ones to be rated at four notches above the Indian sovereign.

Moody's said both technology giants benefit from a highly diversified revenue base across geographies and sectors, strong and consistent profitability, excellent liquidity, a debt-free balance sheet, and sustained robust free cash flow generation.

The ratings agency also upgraded Reliance Industries' (NSE:RELIANCE, BOM:500325) long-term local currency issuer rating and its foreign currency senior unsecured ratings to Baa1 from Baa2, while Tata Steel's (NSE:TATASTEEL, BOM:500470) long-term foreign currency issuer rating has moved up to Baa2 from Baa3.

Moody's said Reliance gains from its leading positions across oil-to-chemicals, digital services, and retail, as well as counter-cyclical business segments and significant international exposure, with more than one-third of revenue coming from exports.

For Tata Steel, Moody's said that the company continues to benefit from its close association with the parent Tata Sons and the broader Tata Group, including the strength of the Tata brand, which supports its access to funding and relationships with lenders and investors.

The outlook for all four Indian companies remains stable, the statement said.

Related Articles

Asia

Genrix Grants CQ Pharmaceutical Distribution Rights for Myeloma Drug in China, Hong Kong, Macau, Taiwan

Chongqing Genrix Biopharmaceutical (SHA:688443) granted C.Q. Pharmaceutical (SHE:000950) subsidiary Yaoyou Pharmaceutical exclusive development and distribution rights for the GR1803 drug across China and Hong Kong, Macau, and Taiwan.The agreement covers development such as clinical trials, research, and manufacturing, as well as sales, the filing said.The GR1803 velitumimumab drug is indicated for multiple myeloma, a rare form of blood cancer.Yaoyou will pay Genrix up to 600 million yuan in initial payment, listing milestone, and technology transfer milestone payments.Genrix will also be eligible to receive sales royalties of up to a minimum percentage of two digits.

SHA:688443SHE:000950
Asia

Xuan Wu Cloud's CFO Steps Down

Xuan Wu Cloud Technology's (HKG:2392) Chief Financial Officer Ge Ping resigned to devote more time to personal affairs effective May 31, according to a Friday Hong Kong bourse filing.

HKG:2392
Asia

Update: Xi'an Eswin Materials Technology to Invest Up to 40 Million Yuan in Glassmaker's Funding Round

Xi'an Eswin Materials Technology (SHA:688783) will invest up to 40 million yuan in a pre-A+ funding round for Zhuhai Yiyuan Technology, according to a Friday filing with the Shanghai bourse.Zhuhai Yiyuan Technology seeks to raise between 100 million yuan and 200 million yuan in a funding round.The glass manufacturer plans to use the proceeds for capacity expansion, equipment procurement, and technology upgrades.

SHA:688783